Clinical Scorecard: Advancing Strategies for the Prevention of Valvular Heart Disease

At a Glance

Key Highlights

• Development of 10-year absolute risk charts for aortic stenosis using routine clinical variables to guide primary prevention
• Identification of modifiable risk factors including hypertension, hyperlipidaemia, diabetes, obesity, smoking, and kidney dysfunction associated with valve calcification and disease
• Emerging composite cardiovascular health scores (e.g., Life’s Essential 8 and Life’s Crucial 9) and proteomic signatures link lifestyle and biological pathways to VHD risk

Guideline-Based Recommendations

Diagnosis

• Use imaging (e.g., echocardiography, CT) to detect aortic valve calcification and sclerosis even before haemodynamic stenosis develops
• Apply risk stratification tools such as the ASGARD risk score incorporating Vmax, NT-proBNP, and heart rate for monitoring asymptomatic non-severe AS

Management

• Intensify lifestyle interventions targeting modifiable risk factors: blood pressure control, lipid management, glycaemic control, weight management, smoking cessation, and physical activity
• Consider sex-specific risk profiles when prioritizing prevention strategies
• Monitor and manage metabolic factors including diabetes and prediabetes to reduce valve disease progression

Monitoring & Follow-up

• Personalize follow-up intervals based on risk scores such as ASGARD to optimize echocardiography scheduling
• Incorporate biomarkers (e.g., NT-proBNP) alongside imaging for surveillance
• Recognize aortic valve sclerosis as a marker for increased cardiovascular risk including myocardial infarction recurrence

Risks

• Higher risk of valve disease progression and cardiovascular events with uncontrolled hypertension, diabetes, obesity, and hyperlipidaemia
• Increased risk associated with consumption of artificially sweetened beverages and sugar-sweetened drinks
• Sex differences in risk factor impact necessitate tailored prevention approaches

Patient & Prescribing Data

Adults at risk for or with early-stage degenerative valvular heart disease, including those with metabolic syndrome or genetic predisposition

Risk factor modification through lifestyle and medical management can reduce incidence and progression; glycaemic control benefits valves before overt diabetes; biomarker-guided monitoring may optimize resource use

Clinical Best Practices

• Implement 10-year absolute risk charts for aortic stenosis in clinical practice to facilitate early prevention discussions
• Screen for and address modifiable cardiovascular and metabolic risk factors comprehensively
• Use composite cardiovascular health scores to guide patient counseling and risk reduction strategies
• Incorporate sex-specific risk assessments to tailor prevention and monitoring
• Apply validated risk scores like ASGARD for safe and efficient surveillance of asymptomatic patients
• Recognize the prognostic significance of aortic valve sclerosis beyond stenosis

References

• Cardiovascular risk factors and aortic valve stenosis: towards 10 year absolute risk charts for primary prevention
• Prevalence and common cardiovascular risk factors in aortic valve calcification in the middle-aged general population
• Sex differences in cardiovascular–kidney–metabolic risk factors associated with degenerative valvular heart disease
• High Life’s Essential 8 score is associated with lower aortic valve calcification
• Aortic stenosis risk and Life’s Crucial 9: the role of proteomics and inflammation
• Diabetes and elevated plasma glucose in heart valve calcification and disease: the Copenhagen General Population Study
• Hyperglycaemia and genetic susceptibility in relation to incident degenerative aortic valve stenosis
• Associations between sweetened beverage consumption, degenerative valvular heart disease, and related events: a prospective study from UK Biobank
• Non-stenotic fibro-calcific aortic valve as a predictor of myocardial infarction recurrence
• Development and validation of the ASGARD risk score for safe monitoring in asymptomatic non-severe aortic valve stenosis